Acumen teams with Lonza for advancement of sabirnetug to treat AD

Acumen Pharmaceuticals (ABOS) has signed a collaboration agreement with Lonza (LZAGY), “a global partner to the pharmaceutical, biotech and nutraceutical markets.” The agreement covers the manufacture of sabirnetug ACU193 , an antibody targeting toxic soluble AbetaOs for the treatment of AD, for clinical development and commercialization, if approved. Under the terms of the agreement, Lonza will manufacture the sabirnetug drug substance at its next-generation, manufacturing facility in Portsmouth, New Hampshire equipped with 2,000L single-use bioreactors. Acumen will leverage Lonza’s regulatory expertise, extensive experience in antibody manufacturing, and global manufacturing network from 2,000L to 20,000L. James Doherty, President and Chief Development Officer, Acumen Pharmaceuticals, added: “As we progress into Phase 2 clinical development of sabirnetug as a potentially best-in-class treatment for early AD, we are acutely aware that patients and their families are in urgent need of safe, effective treatment options for this devastating disease. Partnering with Lonza is a critical step to ensure broader access to next-generation AD therapies.”